Eli Lilly invested in Absci to develop ABS-201, an early-stage hair loss drug designed via AI. The partnership leverages generative AI to accelerate protein design and antibody discovery. This deal validates AI-driven drug discovery for niche therapeutic areas. Practitioners should watch if AI-designed molecules can clear clinical trials faster than traditional methods.